{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00025154", "CSN": null, "TRF": "ORD_1514793_01", "MRN": "43056399", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1232997", "clinicalId": "1234367", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1514793_01", "SampleName": "US1450102.01", "Version": "0", "Sample": {"FM_Id": "ORD_1514793_01", "SampleId": "US1450102.01", "BlockId": "S111-71270M", "TRFNumber": "ORD_1514793_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_12_01", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10028", "MRN": "43056399", "FullName": "\u5b5f\u54e1\u5da0", "FirstName": "Yuan Chiao", "LastName": "Meng", "SubmittedDiagnosis": "Adenocarcinoma, Pancreas", "Gender": "Male", "DOB": "1949_11_22", "OrderingMD": "\u674e\u91cd\u8cd3", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Pancreas", "CollDate": "2022_09_06", "ReceivedDate": "2022-12-12 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Pancreatic Cancer"}, "PertinentNegatives": {"PertinentNegative": {"Gene": "BRCA1"}}, "Summaries": {"alterationCount": "15", "clinicalTrialCount": "13", "resistiveCount": "0", "sensitizingCount": "4"}, "VariantProperties": {"VariantProperty": [{"geneName": "AKT1", "isVUS": "true", "variantName": "I75M"}, {"geneName": "ATM", "isVUS": "true", "variantName": "I2223V"}, {"geneName": "DIS3", "isVUS": "true", "variantName": "A656V"}, {"geneName": "ERBB3", "isVUS": "true", "variantName": "R967K"}, {"geneName": "IDH2", "isVUS": "true", "variantName": "M397V"}, {"geneName": "MSH6", "isVUS": "true", "variantName": "K1358fs*2"}, {"geneName": "PTCH1", "isVUS": "true", "variantName": "D1222N"}, {"geneName": "SMAD4", "isVUS": "true", "variantName": "S271N"}, {"geneName": "TBX3", "isVUS": "true", "variantName": "A562V"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "BRCA2", "Include": "true", "Alterations": {"Alteration": {"Name": "T2125fs*4", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "17.62", "isEquivocal": "false", "name": "T2125fs*4"}}, "Interpretation": "The BRCA2 tumor suppressor gene encodes a protein that regulates the response to DNA damage (Yang et al., 2002; 12228710). Inactivating mutations in BRCA2 can lead to the inability to repair DNA damage and loss of cell cycle checkpoints, which can lead to tumorigenesis (Holloman, 2011; 21731065). Alterations such as seen here may disrupt BRCA2 function or expression (Biswas et al., 2011; 21719596, Biswas et al., 2012; 22678057, Claes et al., 2004; 15026808, Cote et al., 2012; 21947752, Fackenthal et al., 2002; 12145750, Farrugia et al., 2008; 18451181, G\u00f3mez Garc\u00eda et al., 2009; 19200354, Guidugli et al., 2013; 23108138, Kluska et al., 2015; 25948282, Kuznetzov et al., 2008; 18607349, Roy et al., 2012; 22193408, Siaud et al., 2011; 22194698, Thomassen et al., 2006; 16792514, Xia et al., 2006; 16793542, Yang et al., 2002; 12228710, Guidugli et al., 2018; 29394989, Fraile_Bethencourt, et al., 2017; 28339459). BRCA2 mutations have been observed in 1_2% of pancreatic carcinomas (cBio_Witkiewicz et al., 2015; 25855536, cBio_Bailey et al., 2016; 26909576). Germline mutations in BRCA1 and BRCA2 have been linked to an increased risk of pancreatic adenocarcinoma (Hahn et al., 2003; 12569143, Lowery et al., 2011; 21934105, Mocci et al., 2013; 23456555), and BRCA1/2 loss of heterozygosity (LOH) has been reported in 3 of 4 pancreatic ductal adenocarcinomas associated with the BRCA2 germline mutation 6174delT (Lucas et al., 2013; 23658460). Alterations that inactivate BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors (Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Tutt et al., 2010; 20609467, Robson et al., 2017; 28578601, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788, Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934, Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755, Domchek et al., 2016; 26723501, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) or ATR inhibitors (Yap et al., 2020; 32988960, Thomas et al., 2018; 29252124, O Carrigan et al., 2016; ASCO Abstract 2504, Yap et al., 2016; AACR_NCI_EORTC Abstract 1LBA, Saito et al., 2018; 31299005). Clinical responses to PARP inhibitors have been reported for patients with either germline or somatic BRCA1/2 mutations (Mateo et al., 2015; 26510020, Swisher et al., 2016; 27908594, Ledermann et al., 2016; 27617661, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) and for patients with platinum_resistant or _refractory disease (Fong et al., 2010; 20406929, Kaufman et al., 2015; 25366685, Sandhu et al., 2013; 23810788, Domchek et al., 2016; 26723501). A randomized Phase 2 trial evaluating cisplatin and gemcitabine with or without veliparib in 50 patients with advanced pancreatic ductal adenocarcinomas (PDAC) harboring germline BRCA1/2 or PALB2 (gBRCA/PALB2+) mutations reported that the addition of the PARP inhibitor veliparib to chemotherapy did not significantly improve median PFS (10.1 vs. 9.7 months) or median OS (15.5 vs. 16.4 months) relative to chemotherapy alone (O\u2019Reilly et al., 2020; 31976786). The WEE1 inhibitor adavosertib has been evaluated as a monotherapy and in combination with PARP_inhibitor, olaparib. In a Phase 2 study for patients with PARP_resistant ovarian cancer, the combination of olaparib and adavosertib elicited improved clinical benefit (ORR: 29%; DCR: 89%) compared to adavosertib alone (ORR: 23%; DCR: 63%); however, in the BRCA_mutated cohort, no significant difference in clinical benefit was observed between the combination (ORR: 19%) and monotherapy (ORR: 20%) treatments (Westin et al., 2021; ASCO Abstract 5505). In a Phase 1 monotherapy trial of adavosertib that included 9 patients with BRCA1/2_mutated solid tumors, 2 patients with BRCA1_mutated cancers (1 with ovarian serous carcinoma and 1 with oral squamous cell carcinoma) achieved PRs, and a third patient with ovarian serous carcinoma harboring mutations in BRCA1 and TP53 experienced 14% tumor shrinkage prior to disease progression (Do et al., 2015; 25964244). In a case study, a patient with therapy_induced neuroendocrine prostate cancer and an inactivating BRCA2 rearrangement experienced a CR ongoing for 20 months to the ATR inhibitor berzosertib (Saito et al., 2018; 31299005). Preclinical studies of BRCA1/2 inactivation in T_cell acute lymphoblastic leukemia (T_ALL) (Pouliot et al., 2019; 31721781), ovarian carcinoma (Kim et al., 2017; 27993965), and triple_negative breast cancer (TNBC) (Jin et al., 2018; 29605721) showing reduced cell viability and increased DNA damage during ATR treatment further support the sensitivity of BRCA2_deficient cells to ATR inhibitors. The Phase 1/2 PETRA study of PARP1 inhibitor AZD5305 observed a 25% (10/40) ORR (10 PR), for patients with BRCA1/2, PALB2, or RAD51C_mutated breast, ovarian, pancreatic, or prostate cancer, including 5 patients with prior PARP inhibitor treatment (Yap et al., 2022; AACR Abstract CT007). Inactivation of BRCA2 may also predict sensitivity to DNA_damaging drugs such as trabectedin, lurbinectedin, and the platinum chemotherapies cisplatin and carboplatin (Isakoff et al., 2015; 25847936, Dann et al., 2012; 22406760, Evers et al., 2008; 18559613, Soares et al., 2007; 17656556, Miolo et al., 2016; 27561088, Ghouadni et al., 2017; 28467918, Tedesco et al., 2011; ASCO Abstract 1125, Perez et al., 2017; 28626402, Monk et al., 2020; 31924332, Harnicek et al., 2016; 26933761, Cruz et al., 2018; 30240327, Awada et al., 2018; ASCO Abstract 1072, Poveda et al., 2017; 28368437). Patients with pancreatic cancer and BRCA1/2 or PALB2 mutations may benefit from FOLFIRINOX, or the combination of cisplatin and gemcitabine (NCCN Pancreatic Adenocarcinoma Guidelines, v1.2022)(Conroy et al., 2011; 21561347, Fogelman et al., 2015; 26126726,O\u2019Reilly et al., 2020; 31976786, Wattenberg et al., 2020; 31787751, Golan et al., 2014; 25072261). One or more of the BRCA2 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hereditary breast and ovarian cancer syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Inactivating germline mutations in BRCA1 or BRCA2 are associated with autosomal dominant hereditary breast and ovarian cancer (Miki et al., 1994; 7545954, Wooster et al., 1995; 8524414), and the lifetime risk of breast and ovarian cancer in BRCA2 mutation carriers has been estimated to be as high as >80% and 23%, respectively (King et al., 2003; 14576434). Elevated risk for other cancer types, including gastric, pancreatic, prostate, and colorectal, has also been identified, with an increase in risk ranging from 20 to 60% (Friedenson, 2005; 16369438). The estimated prevalence of deleterious germline BRCA1/2 mutations in the general population is between 1:400 and 1:800, with an approximately 10_fold higher prevalence in the Ashkenazi Jewish population (Ford et al., 1994; 7907678, Whittemore et al., 1997; 9042908, Claus et al., 1996; 8635102, Struewing et al., 1997; 9145676, Oddoux et al., 1996; 8841192, King et al., 2003; 14576434, Hall et al., 2009; 19241424). In the appropriate clinical context, germline testing of BRCA2 is recommended.", "Include": "true", "ClinicalTrialNote": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Talazoparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor talazoparib is FDA approved to treat HER2_negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical data in breast cancer (Turner et al., 2017; ASCO Abstract 1007)(Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753) and additional clinical evidence in ovarian, pancreatic, and prostate cancer (Meehan et al., 2017; AACR Abstract 4687)(de Bono et al., 2017; 28242752, Lu et al., 2018; 30099369, De Bono et al., 2020; ASCO Abstract 5566), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib. </p> <p><b>Supporting Data:</b> A Phase 1 study of talazoparib reported PRs for 20% (2/10) of patients with pancreatic cancer, 1 with a BRCA2 mutation and 1 with a PALB2 mutation (deBono et al., 2017; 28242752). Talazoparib has been studied primarily in the context of BRCA_mutated, HER2_negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study (Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753). In a Phase 2 study of talazoparib for BRCA1/2_wildtype patients with homologous recombination pathway alterations, the best outcome in non_breast tumors was SD \u2265 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration (Gruber et al., 2019; ASCO Abstract 3006). Clinical activity of single_agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA_mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2_mutated pancreatic and bladder cancers; ATM_mutated cholangiocarcinoma; and small cell lung cancer (deBono et al., 2017; 28242752, Lu et al., 2018; 30099369)(Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096, Meehan et al., 2017; AACR Abstract 4687). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Olaparib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA_mutated pancreatic adenocarcinoma or HER2_negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of extensive clinical evidence in ovarian cancer (Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755) as well as strong clinical evidence in multiple other cancer types (Fong et al., 2009; 19553641, Tutt et al., 2010; 20609467, Gelmon et al., 2011; 21862407, Del Conte et al., 2014; 25025963, Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Golan et al., 2019; 31157963), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib. </p> <p><b>Supporting Data:</b> The Phase 3 randomized, placebo_controlled POLO trial investigating maintenance olaparib for patients with platinum_sensitive, germline BRCA1/2_mutated metastatic pancreatic adenocarcinoma reported a significantly longer median PFS compared with placebo (7.4 vs. 3.8 months, HR=0.53) (Golan et al., 2019; 31157963). At 3_year follow_up, an OS of 34% was reported for patients treated with olaparib compared with 18% for patients receiving placebo; however, olaparib maintenance therapy did not impact median OS (19.0 vs. 19.2 months, HR=0.83) relative to placebo (Golan et al., 2021; ASCO Abstract 378). A Phase 2 trial of olaparib monotherapy for patients with germline BRCA1/2_mutated recurrent pancreatic cancer reported a response rate of 22% (Kaufman et al., 2015; 25366685). Parallel Phase 2 trials reported 2 PRs for patients with platinum_sensitive, DNA damage repair (DDR) deficient, germline BRCA mutation_negative pancreatic ductal adenocarcinoma; no responses were observed in platinum_refractory cases (Golan et al., 2018; ASCO Abstract 297). In a Phase 2 study of olaparib plus pembrolizumab for advanced solid tumors, patients with BRCA1 or BRCA2 mutations achieved an ORR of 29% (6/21), whereas patients with mutations in other homologous recombination repair genes achieved an ORR of 6.3% (2/32) (Maio et al., 2021; AACR Abstract CT178). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Rucaparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration_resistant prostate cancer (mCRPC) and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence in ovarian cancer (Shapira_Frommer et al., 2015; ASCO Abstract 5513)(Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934), as well as clinical data in other cancer types (Kristeleit et al., 2014; ASCO Abstract 2573, Domcheck et al., 2016; ASCO Abstract 4110)(Drew et al., 2016; 27002934), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib. </p> <p><b>Supporting Data:</b> In the RUCAPANC Phase 2 study, rucaparib elicited an ORR of 16% and a DCR of 32% for BRCA1/2_mutated advanced or metastatic pancreatic cancer, with 2 CRs (1 confirmed, 1 unconfirmed) and 2 PRs out of 19 treated patients (Shroff et al., 2018; 30051098). As maintenance therapy for BRCA1/2_ or PALB2_mutated platinum_sensitive pancreatic cancer, rucaparib enabled a 6_month PFS rate of 60%, median PFS and OS of 13.1 and 23.5 months, and ORR of 41% (3/36 CRs, 2 ongoing for >1 year) in a Phase 2 study; 4 patients remained progression_free during >2 years of follow up (Reiss et al., 2021; 33970687, Binder et al., 2019; AACR Abstract CT234). In this trial, ORRs for patients with germline or somatic BRCA2 alterations were 41% (11/27) and 50% (1/2), respectively, and 50% (3/6) for those with germline PALB2 alterations; however, no objective responses were observed for any of 7 patients with germline BRCA1 alterations (Reiss et al., 2021; 33970687). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Niraparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)_positive status. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in ovarian and breast cancers (Konstantinopolous et al., 2018; ASCO Abstract 106, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib. </p> <p><b>Supporting Data:</b> In a Phase 1b/2 study, 6_month PFS for patients with advanced pancreatic cancer treated with niraparib plus ipilimumab in the maintenance setting was 60% whereas those treated with niraparib plus nivolumab was 21% (Reiss et al., 2022; 35810751). Niraparib has been primarily evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum_sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination_deficient tumors (12.9 vs. 3.8 months)(Mirza et al., 2016; 27717299). In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration_resistant prostate cancer and 100% (2/2) of patients with non_small cell lung cancer achieved SD (Sandhu et al., 2013; 23810788). A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum_sensitive, high_grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)(Mirza et al., 2016; ASCO Abstract 5555). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04300114", "Include": "true"}, {"nctId": "NCT04644068", "Include": "true"}, {"nctId": "NCT04228601", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04425876", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "G12D", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "15.57", "isEquivocal": "false", "name": "G12D"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870, Loree et al., 2021; 34117033). KRAS mutations have been observed in 91_95% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, cBio_Witkiewicz et al., 2015; 25855536), with the majority of mutations found at codon 12 (Feldmann et al., 2007; 17520196, Rachakonda et al., 2013; 23565280, Hruban et al., 1993; 8342602, Maitra et al., 2006; 16549325). KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma (Rachakonda et al., 2013; 23565280). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). For patients with pancreatic cancer, MEK inhibitor combinations are under investigation. A Phase 2 study of trametinib with pembrolizumab versus gemcitabine after stereotactic body radiotherapy (SBRT) reported increased median OS (mOS, 14.9 months vs. 12.8 months, HR=0.69) benefit for patients with KRAS_mutated, PD_L1 positive disease (Zhu et al., 2022; 35240087). Combination MEK/autophagy inhibitors are also under investigation based on preclinical evidence of increased autophagy downstream of KRAS_mutated pancreatic tumors (Kinsey et al., 2019; 30833748, Bryant et al., 2019; 30833752). A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine experienced a PR (Kinsey et al., 2019; 30833748). A Phase 2 study of the reoviral agent pelareorep with gemcitabine for patients with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs for 34 patients with a favorable median OS of 10.2 months (Mahalingam et al., 2018; 29799479). A Phase 1b study of second_line pelareorep with pembrolizumab and chemotherapy reported 1 PR of 17.4 months and a DCR of 30% (3/10) (Mahalingham et al., 2020;31694832); an earlier study reported no benefit from pelareorep in combination with paclitaxel/carboplatin (Noonan et al., 2016; 27039845). Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors (Ko et al., 2016; 26251290) or PI3K_AKT pathway inhibitors (LoRusso et al., 2012; ASCO Abstract 2566, Juric et al., 2014; ASCO Abstract 9051, Chung et al., 2017; 27978579, Bedard et al., 2015; 25500057), reported no PRs and frequent adverse events for patients with KRAS_mutated pancreatic cancer. Clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status (Van Laethem et al., 2017; 27975152, Infante et al., 2013; 23583440, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), despite promising results in earlier trials of MEK inhibitor monotherapies (Bodoky et al., 2012; 21594619, Rosen et al., 2008; ASCO Abstract 14585, Rinehart et al., 2004; 15483017, LoRusso et al., 2005; 16009947, Bodoky et al., 2012; 21594619, Infante et al., 2012; 22805291, Weekes et al., 2013; 23434733, Rinehart et al., 2004; 15483017, Infante et al., 2012; 22805291, Garrido_Laguna et al., 2015; 25897431). In a Phase 1 study evaluating the MEK_pan_RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non_small cell lung cancer (NCSLC), 1 with low_grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma (Guo et al., 2020; 33128873). Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS_mutated low_grade serous ovarian cancer and 12% (2/17) for patients with KRAS_mutated non_small cell lung cancer (NSCLC) in a Phase 1 study (Krebs et al., 2021; AACR Abstract CT019, Shinde et al., 2020; AACR Abstract CT143). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors (Hillig et al., 2019; 30683722, Hofmann et al., 2021; 32816843, Gerlach et al., 2020; AACR Abstract 1091). Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations (Hofmann et al., 2021; AACR Abstract CT210, Gort et al., 2020; ASCO Abstract TPS3651).", "Include": "true", "ClinicalTrialNote": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03825289", "Include": "true"}, {"nctId": "NCT04892017", "Include": "true"}, {"nctId": "NCT04132505", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": {"Name": "p16INK4a H83Y and p14ARF A97V", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "16.82", "isEquivocal": "false", "name": "p16INK4a H83Y and p14ARF A97V"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here have been observed in the context of cancer but have not been characterized and their effect on p14ARF function is unclear. CDKN2A/B loss has been reported in 36% of pancreatic ductal carcinomas (Witkiewicz et al., 2015; 25855536). CDKN2A loss has been reported in 25_100% of pancreatic ductal adenocarcinomas analyzed, with a portion of those due to gene deletion (Tsiambas et al., 2007; 17600882, Bergmann et al., 2006; 16497872, Attri et al., 2005; 15985168, Rachakonda et al., 2013; 23565280). A study of multiple pancreatic cancer subtypes reported no CDKN2A mutations (0/6 samples) and loss of heterozygosity in only one of four samples of pancreatic acinar carcinomas, compared to mutation or loss of heterozygosity in 38% and 67% of pancreatic ductal carcinomas, respectively (Moore et al., 2001; 11161385). Promoter methylation affecting p16INK4a and p14ARF has been reported in 43% (16/37) and 20.6% (7/34), respectively, of pancreatic fluid specimens of patients with pancreatic carcinoma (Klump et al., 2003; 12610506). The loss or decrease of p16INK4a expression levels in pancreatic ductal adenocarcinoma has been reported in 32_80% of samples analyzed and one study reported concurrent loss of p16INK4a and p14ARF protein expression in 68% (19/28) of cases (Oshima et al., 2013; 23470568, Tsiambas et al., 2007; 17600882, Geradts et al., 2001; 11706079). p16INK4a expression has been associated with improved overall survival in pancreatic adenocarcinoma patients in univariate and multivariate analysis (Chang et al., 2010; 20665497). Furthermore, CDKN2A alterations (deletion or mutation) in the presence of concomitant KRAS mutation may correlate with shorter survival in patients with pancreatic ductal adenocarcinoma (Oshima et al., 2013; 23470568). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)(Hu et al., 2018; 29367431, Campbell et al., 2017; 29056344, Pihlak et al., 2018; 29329208, Salem et al., 2018; 29523759, Lahgi et al., 2012; 23029359). The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "Q192*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "17.46", "isEquivocal": "false", "name": "Q192*"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 33_75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, Morton et al., 2010; 20018721, Scarpa et al., 1993; 8494051, Luo et al., 2013; 22782330). TP53 mutations are common in pancreatic ductal adenocarcinomas and are known to occur in the process of pancreatic carcinogenesis (Iacobuzio_Donahue et al., 2012; 22896692, Macgregor_Das and Iacobuzio_Donahue, 2013; 22806689). Additionally, aberrant expression of p53 has been found in 54_81% of pancreatic ductal adenocarcinoma cases (Oshima et al., 2013; 23470568, Ottenhof et al., 2012; 22351431, Tsiambas et al., 2010; 20414934, Scarpa et al., 1993; 8494051). Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis (Ansari et al., 2011; 21644238, Oshima et al., 2013; 23470568, Grochola et al., 2011; 21404460). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Pancreatic carcinomas, including ductal and acinar subtypes, have been reported to harbor a median TMB of 2_3 mutations per megabase (muts/Mb), and 0_2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421); TMB has not been assessed in pancreatic mucinous neoplasms (PubMed, Oct 2022). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69_314 months) compared to those with lower TMB (average of 5.7 mutations; 10_42 months) (Hu et al., 2017; ASCO Abstract e15791). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum_Based Chemotherapy", "StudyPhase": "PHASE 3", "Target": "PARP", "Locations": "Hangzhou (China), Shanghai (China), Nanjing (China), Hefei (China), Guangzhou (China), Wuhan (China), Zhengzhou (China), Jinan (China), Chongqing (China), Tianjin (China)", "NCTID": "NCT04300114", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "ERBB2, TROP2, PARP", "Locations": "Shanghai (China), Guangzhou (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Bydgoszcz (Poland)", "NCTID": "NCT04644068", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer", "StudyPhase": "PHASE 1/2", "Target": "PARP", "Locations": "Hangzhou (China), Shanghai (China)", "NCTID": "NCT04228601", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Shanghai (China)", "NCTID": "NCT04425876", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Nedlands (Australia), Darlinghurst (Australia), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Beer_Sheva (Israel), Istanbul (Turkey)", "NCTID": "NCT03742895", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "T2125fs*4", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Utah", "NCTID": "NCT03825289", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "A Safety, Tolerability and PK Study of DCC_3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1/2", "Target": "ULK1, ULK2, MEK", "Locations": "Massachusetts, Texas, Pennsylvania", "NCTID": "NCT04892017", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12D", "Title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Texas", "NCTID": "NCT04132505", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "1", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "2", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "3", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "4", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "5", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "6", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "7", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "8", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "9", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "10", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "11", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "12", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "13", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "14", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "15", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "16", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "17", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "18", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "19", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "20", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "21", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "22", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "23", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "24", "ReferenceId": "34117033", "FullCitation": "Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033", "Include": "true"}, {"number": "25", "ReferenceId": "23103869", "FullCitation": "Biankin AV, et al. Nature (2012) pmid: 23103869", "Include": "true"}, {"number": "26", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "27", "ReferenceId": "17520196", "FullCitation": "Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196", "Include": "true"}, {"number": "28", "ReferenceId": "23565280", "FullCitation": "Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280", "Include": "true"}, {"number": "29", "ReferenceId": "8342602", "FullCitation": "Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602", "Include": "true"}, {"number": "30", "ReferenceId": "16549325", "FullCitation": "Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325", "Include": "true"}, {"number": "31", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "32", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "33", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "34", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "35", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "36", "ReferenceId": "35240087", "FullCitation": "Zhu X, et al. Lancet Oncol (2022) pmid: 35240087", "Include": "true"}, {"number": "37", "ReferenceId": "30833748", "FullCitation": "Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748", "Include": "true"}, {"number": "38", "ReferenceId": "30833752", "FullCitation": "Bryant KL, et al. Nat. Med. (2019) pmid: 30833752", "Include": "true"}, {"number": "39", "ReferenceId": "29799479", "FullCitation": "Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479", "Include": "true"}, {"number": "40", "ReferenceId": "31694832", "FullCitation": "Mahalingam D, et al. Clin. Cancer Res. (2019) pmid: 31694832", "Include": "true"}, {"number": "41", "ReferenceId": "27039845", "FullCitation": "Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845", "Include": "true"}, {"number": "42", "ReferenceId": "26251290", "FullCitation": "Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290", "Include": "true"}, {"number": "43", "ReferenceId": "27978579", "FullCitation": "Chung V, et al. JAMA Oncol (2017) pmid: 27978579", "Include": "true"}, {"number": "44", "ReferenceId": "25500057", "FullCitation": "Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057", "Include": "true"}, {"number": "45", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "46", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "47", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "48", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "49", "ReferenceId": "21594619", "FullCitation": "Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619", "Include": "true"}, {"number": "50", "ReferenceId": "15483017", "FullCitation": "Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017", "Include": "true"}, {"number": "51", "ReferenceId": "16009947", "FullCitation": "Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947", "Include": "true"}, {"number": "52", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "53", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "54", "ReferenceId": "25897431", "FullCitation": "Garrido_Laguna I, et al. Oncoscience (2015) pmid: 25897431", "Include": "true"}, {"number": "55", "ReferenceId": "33128873", "FullCitation": "Guo C, et al. Lancet Oncol (2020) pmid: 33128873", "Include": "true"}, {"number": "56", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "57", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "58", "ReferenceId": "30683722", "FullCitation": "Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722", "Include": "true"}, {"number": "59", "ReferenceId": "32816843", "FullCitation": "Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843", "Include": "true"}, {"number": "60", "ReferenceId": "12228710", "FullCitation": "Yang H, et al. Science (2002) pmid: 12228710", "Include": "true"}, {"number": "61", "ReferenceId": "21731065", "FullCitation": "Nat. Struct. Mol. Biol. (2011) pmid: 21731065", "Include": "true"}, {"number": "62", "ReferenceId": "21719596", "FullCitation": "Biswas K, et al. Blood (2011) pmid: 21719596", "Include": "true"}, {"number": "63", "ReferenceId": "22678057", "FullCitation": "Biswas K, et al. Hum. Mol. Genet. (2012) pmid: 22678057", "Include": "true"}, {"number": "64", "ReferenceId": "15026808", "FullCitation": "Claes K, et al. Br. J. Cancer (2004) pmid: 15026808", "Include": "true"}, {"number": "65", "ReferenceId": "21947752", "FullCitation": "Cote S, et al. Breast Cancer Res. Treat. (2012) pmid: 21947752", "Include": "true"}, {"number": "66", "ReferenceId": "12145750", "FullCitation": "Fackenthal JD, et al. Am. J. Hum. Genet. (2002) pmid: 12145750", "Include": "true"}, {"number": "67", "ReferenceId": "18451181", "FullCitation": "Farrugia DJ, et al. Cancer Res. (2008) pmid: 18451181", "Include": "true"}, {"number": "68", "ReferenceId": "19200354", "FullCitation": "G\u00f3mez Garc\u00eda EB, et al. Breast Cancer Res. (2009) pmid: 19200354", "Include": "true"}, {"number": "69", "ReferenceId": "23108138", "FullCitation": "Guidugli L, et al. Cancer Res. (2013) pmid: 23108138", "Include": "true"}, {"number": "70", "ReferenceId": "25948282", "FullCitation": "Kluska A, et al. BMC Med Genomics (2015) pmid: 25948282", "Include": "true"}, {"number": "71", "ReferenceId": "18607349", "FullCitation": "Kuznetsov SG, et al. Nat. Med. (2008) pmid: 18607349", "Include": "true"}, {"number": "72", "ReferenceId": "22193408", "FullCitation": "Roy R, et al. Nat. Rev. Cancer (2011) pmid: 22193408", "Include": "true"}, {"number": "73", "ReferenceId": "22194698", "FullCitation": "Siaud N, et al. PLoS Genet. (2011) pmid: 22194698", "Include": "true"}, {"number": "74", "ReferenceId": "16792514", "FullCitation": "Thomassen M, et al. Genet. Test. (2006) pmid: 16792514", "Include": "true"}, {"number": "75", "ReferenceId": "16793542", "FullCitation": "Xia B, et al. Mol. Cell (2006) pmid: 16793542", "Include": "true"}, {"number": "76", "ReferenceId": "29394989", "FullCitation": "Guidugli L, et al. Am. J. Hum. Genet. (2018) pmid: 29394989", "Include": "true"}, {"number": "77", "ReferenceId": "28339459", "FullCitation": "Fraile_Bethencourt E, et al. PLoS Genet. (2017) pmid: 28339459", "Include": "true"}, {"number": "78", "ReferenceId": "26909576", "FullCitation": "Bailey P, et al. Nature (2016) pmid: 26909576", "Include": "true"}, {"number": "79", "ReferenceId": "12569143", "FullCitation": "Hahn SA, et al. J. Natl. Cancer Inst. (2003) pmid: 12569143", "Include": "true"}, {"number": "80", "ReferenceId": "21934105", "FullCitation": "Lowery MA, et al. Oncologist (2011) pmid: 21934105", "Include": "true"}, {"number": "81", "ReferenceId": "23456555", "FullCitation": "Mocci E, et al. Cancer Epidemiol. Biomarkers Prev. (2013) pmid: 23456555", "Include": "true"}, {"number": "82", "ReferenceId": "23658460", "FullCitation": "Lucas AL, et al. Clin. Cancer Res. (2013) pmid: 23658460", "Include": "true"}, {"number": "83", "ReferenceId": "25366685", "FullCitation": "Kaufman B, et al. J. Clin. Oncol. (2015) pmid: 25366685", "Include": "true"}, {"number": "84", "ReferenceId": "26510020", "FullCitation": "Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020", "Include": "true"}, {"number": "85", "ReferenceId": "20609467", "FullCitation": "Tutt A, et al. Lancet (2010) pmid: 20609467", "Include": "true"}, {"number": "86", "ReferenceId": "28578601", "FullCitation": "Robson M, et al. N. Engl. J. Med. (2017) pmid: 28578601", "Include": "true"}, {"number": "87", "ReferenceId": "27717299", "FullCitation": "Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299", "Include": "true"}, {"number": "88", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "89", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "90", "ReferenceId": "27002934", "FullCitation": "Drew Y, et al. Br. J. Cancer (2016) pmid: 27002934", "Include": "true"}, {"number": "91", "ReferenceId": "28754483", "FullCitation": "Pujade_Lauraine E, et al. Lancet Oncol. (2017) pmid: 28754483", "Include": "true"}, {"number": "92", "ReferenceId": "27617661", "FullCitation": "Ledermann JA, et al. Lancet Oncol. (2016) pmid: 27617661", "Include": "true"}, {"number": "93", "ReferenceId": "19553641", "FullCitation": "Fong PC, et al. N. Engl. J. Med. (2009) pmid: 19553641", "Include": "true"}, {"number": "94", "ReferenceId": "20609468", "FullCitation": "Audeh MW, et al. Lancet (2010) pmid: 20609468", "Include": "true"}, {"number": "95", "ReferenceId": "20406929", "FullCitation": "Fong PC, et al. J. Clin. Oncol. (2010) pmid: 20406929", "Include": "true"}, {"number": "96", "ReferenceId": "21862407", "FullCitation": "Gelmon KA, et al. Lancet Oncol. (2011) pmid: 21862407", "Include": "true"}, {"number": "97", "ReferenceId": "22203755", "FullCitation": "Kaye SB, et al. J. Clin. Oncol. (2012) pmid: 22203755", "Include": "true"}, {"number": "98", "ReferenceId": "26723501", "FullCitation": "Domchek SM, et al. Gynecol. Oncol. (2016) pmid: 26723501", "Include": "true"}, {"number": "99", "ReferenceId": "30345884", "FullCitation": "Moore K, et al. N. Engl. J. Med. (2018) pmid: 30345884", "Include": "true"}, {"number": "100", "ReferenceId": "31157963", "FullCitation": "Golan T, et al. N. Engl. J. Med. (2019) pmid: 31157963", "Include": "true"}, {"number": "101", "ReferenceId": "32988960", "FullCitation": "Yap TA, et al. Cancer Discov (2021) pmid: 32988960", "Include": "true"}, {"number": "102", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "103", "ReferenceId": "31299005", "FullCitation": "Saito YD, et al. Cancer Treat Res Commun (2018) pmid: 31299005", "Include": "true"}, {"number": "104", "ReferenceId": "31976786", "FullCitation": "O Reilly EM, et al. J. Clin. Oncol. (2020) pmid: 31976786", "Include": "true"}, {"number": "105", "ReferenceId": "25964244", "FullCitation": "Do K, et al. J. Clin. Oncol. (2015) pmid: 25964244", "Include": "true"}, {"number": "106", "ReferenceId": "31721781", "FullCitation": "Pouliot GP, et al. PLoS ONE (2019) pmid: 31721781", "Include": "true"}, {"number": "107", "ReferenceId": "27993965", "FullCitation": "Kim H, et al. Clin. Cancer Res. (2017) pmid: 27993965", "Include": "true"}, {"number": "108", "ReferenceId": "29605721", "FullCitation": "Jin J, et al. Neoplasia (2018) pmid: 29605721", "Include": "true"}, {"number": "109", "ReferenceId": "25847936", "FullCitation": "Isakoff SJ, et al. J. Clin. Oncol. (2015) pmid: 25847936", "Include": "true"}, {"number": "110", "ReferenceId": "22406760", "FullCitation": "Dann RB, et al. Gynecol. Oncol. (2012) pmid: 22406760", "Include": "true"}, {"number": "111", "ReferenceId": "18559613", "FullCitation": "Evers B, et al. Clin. Cancer Res. (2008) pmid: 18559613", "Include": "true"}, {"number": "112", "ReferenceId": "17656556", "FullCitation": "Soares DG, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17656556", "Include": "true"}, {"number": "113", "ReferenceId": "27561088", "FullCitation": "Miolo G, et al. Cancer Biol. Ther. (2016) pmid: 27561088", "Include": "true"}, {"number": "114", "ReferenceId": "28467918", "FullCitation": "Ghouadni A, et al. Breast (2017) pmid: 28467918", "Include": "true"}, {"number": "115", "ReferenceId": "28626402", "FullCitation": "Case Rep Oncol () pmid: 28626402", "Include": "true"}, {"number": "116", "ReferenceId": "31924332", "FullCitation": "Monk BJ, et al. Gynecol. Oncol. (2020) pmid: 31924332", "Include": "true"}, {"number": "117", "ReferenceId": "26933761", "FullCitation": "Harnicek D, et al. Int. J. Cancer (2016) pmid: 26933761", "Include": "true"}, {"number": "118", "ReferenceId": "30240327", "FullCitation": "Cruz C, et al. J. Clin. Oncol. (2018) pmid: 30240327", "Include": "true"}, {"number": "119", "ReferenceId": "28368437", "FullCitation": "Poveda A, et al. Ann. Oncol. (2017) pmid: 28368437", "Include": "true"}, {"number": "120", "ReferenceId": "21561347", "FullCitation": "Conroy T, et al. N Engl J Med (2011) pmid: 21561347", "Include": "true"}, {"number": "121", "ReferenceId": "26126726", "FullCitation": "Fogelman D, et al. Cancer Chemother Pharmacol (2015) pmid: 26126726", "Include": "true"}, {"number": "122", "ReferenceId": "31787751", "FullCitation": "Wattenberg MM, et al. Br J Cancer (2020) pmid: 31787751", "Include": "true"}, {"number": "123", "ReferenceId": "25072261", "FullCitation": "Golan T, et al. Br J Cancer (2014) pmid: 25072261", "Include": "true"}, {"number": "124", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "125", "ReferenceId": "7545954", "FullCitation": "Miki Y, et al. Science (1994) pmid: 7545954", "Include": "true"}, {"number": "126", "ReferenceId": "8524414", "FullCitation": "Wooster R, et al. Nature () pmid: 8524414", "Include": "true"}, {"number": "127", "ReferenceId": "14576434", "FullCitation": "King MC, et al. Science (2003) pmid: 14576434", "Include": "true"}, {"number": "128", "ReferenceId": "16369438", "FullCitation": "MedGenMed (2005) pmid: 16369438", "Include": "true"}, {"number": "129", "ReferenceId": "7907678", "FullCitation": "Ford D, et al. Lancet (1994) pmid: 7907678", "Include": "true"}, {"number": "130", "ReferenceId": "9042908", "FullCitation": "Whittemore AS, et al. Am. J. Hum. Genet. (1997) pmid: 9042908", "Include": "true"}, {"number": "131", "ReferenceId": "8635102", "FullCitation": "Claus EB, et al. Cancer (1996) pmid: 8635102", "Include": "true"}, {"number": "132", "ReferenceId": "9145676", "FullCitation": "Struewing JP, et al. N. Engl. J. Med. (1997) pmid: 9145676", "Include": "true"}, {"number": "133", "ReferenceId": "8841192", "FullCitation": "Oddoux C, et al. Nat. Genet. (1996) pmid: 8841192", "Include": "true"}, {"number": "134", "ReferenceId": "19241424", "FullCitation": "Hall MJ, et al. Cancer (2009) pmid: 19241424", "Include": "true"}, {"number": "135", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "136", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "137", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "138", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "139", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "140", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "141", "ReferenceId": "29367431", "FullCitation": "Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431", "Include": "true"}, {"number": "142", "ReferenceId": "29056344", "FullCitation": "Campbell BB, et al. Cell (2017) pmid: 29056344", "Include": "true"}, {"number": "143", "ReferenceId": "29329208", "FullCitation": "Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208", "Include": "true"}, {"number": "144", "ReferenceId": "29523759", "FullCitation": "Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759", "Include": "true"}, {"number": "145", "ReferenceId": "23029359", "FullCitation": "Laghi L, et al. PLoS ONE (2012) pmid: 23029359", "Include": "true"}, {"number": "146", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "147", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "148", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "149", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "150", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "151", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "152", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "153", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "154", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "155", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "156", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "157", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "158", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "159", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "160", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "161", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "162", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "163", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "164", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "165", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "166", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "167", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "168", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "169", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "170", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "171", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "172", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "173", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "174", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "175", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "176", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "177", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "178", "ReferenceId": "17600882", "FullCitation": "Tsiambas E, et al. J BUON () pmid: 17600882", "Include": "true"}, {"number": "179", "ReferenceId": "16497872", "FullCitation": "Bergmann F, et al. J. Clin. Pathol. (2006) pmid: 16497872", "Include": "true"}, {"number": "180", "ReferenceId": "15985168", "FullCitation": "Attri J, et al. BMC Gastroenterol (2005) pmid: 15985168", "Include": "true"}, {"number": "181", "ReferenceId": "11161385", "FullCitation": "Moore PS, et al. Br. J. Cancer (2001) pmid: 11161385", "Include": "true"}, {"number": "182", "ReferenceId": "12610506", "FullCitation": "Klump B, et al. Br. J. Cancer (2003) pmid: 12610506", "Include": "true"}, {"number": "183", "ReferenceId": "23470568", "FullCitation": "Oshima M, et al. Ann. Surg. (2013) pmid: 23470568", "Include": "true"}, {"number": "184", "ReferenceId": "11706079", "FullCitation": "Geradts J, et al. Mod. Pathol. (2001) pmid: 11706079", "Include": "true"}, {"number": "185", "ReferenceId": "20665497", "FullCitation": "Chang DT, et al. Cancer (2010) pmid: 20665497", "Include": "true"}, {"number": "186", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "187", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "188", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "189", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "190", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "191", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "192", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "193", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "194", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "195", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "196", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "197", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "198", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "199", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "200", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "201", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "202", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "203", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "204", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "205", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "206", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "207", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "208", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "209", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "210", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "211", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "212", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "213", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "214", "ReferenceId": "20018721", "FullCitation": "Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018721", "Include": "true"}, {"number": "215", "ReferenceId": "8494051", "FullCitation": "Scarpa A, et al. Am. J. Pathol. (1993) pmid: 8494051", "Include": "true"}, {"number": "216", "ReferenceId": "22782330", "FullCitation": "Luo Y, et al. Pathol. Oncol. Res. (2013) pmid: 22782330", "Include": "true"}, {"number": "217", "ReferenceId": "22896692", "FullCitation": "Iacobuzio_Donahue CA, et al. Clin. Cancer Res. (2012) pmid: 22896692", "Include": "true"}, {"number": "218", "ReferenceId": "22806689", "FullCitation": "Macgregor_Das AM, et al. J Surg Oncol (2013) pmid: 22806689", "Include": "true"}, {"number": "219", "ReferenceId": "22351431", "FullCitation": "Ottenhof NA, et al. Cell Oncol (Dordr) (2012) pmid: 22351431", "Include": "true"}, {"number": "220", "ReferenceId": "20414934", "FullCitation": "Tsiambas E, et al. J BUON () pmid: 20414934", "Include": "true"}, {"number": "221", "ReferenceId": "21644238", "FullCitation": "Ansari D, et al. Br J Surg (2011) pmid: 21644238", "Include": "true"}, {"number": "222", "ReferenceId": "21404460", "FullCitation": "Grochola LF, et al. Pancreas (2011) pmid: 21404460", "Include": "true"}, {"number": "223", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "224", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "225", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "226", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "227", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "228", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "229", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "230", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "231", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "232", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "233", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "234", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "235", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "236", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "237", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "238", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "239", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "240", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "241", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "242", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "243", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "244", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "245", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "246", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "247", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "248", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "249", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "250", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "251", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "252", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "253", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "254", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "255", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "256", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "257", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "258", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "259", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "260", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "261", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "262", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "263", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "264", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "265", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "266", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "267", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "268", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "269", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "270", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "271", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "272", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "273", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "274", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "275", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "276", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "277", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "278", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "279", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "280", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "281", "ReferenceId": "30051098", "FullCitation": "Shroff RT, et al. JCO Precis Oncol (2018) pmid: 30051098", "Include": "true"}, {"number": "282", "ReferenceId": "33970687", "FullCitation": "Reiss KA, et al. J Clin Oncol (2021) pmid: 33970687", "Include": "true"}, {"number": "283", "ReferenceId": "25025963", "FullCitation": "Del Conte G, et al. Br. J. Cancer (2014) pmid: 25025963", "Include": "true"}, {"number": "284", "ReferenceId": "35810751", "FullCitation": "Reiss KA, et al. Lancet Oncol (2022) pmid: 35810751", "Include": "true"}, {"number": "285", "ReferenceId": "30110579", "FullCitation": "Litton JK, et al. N. Engl. J. Med. (2018) pmid: 30110579", "Include": "true"}, {"number": "286", "ReferenceId": "30124753", "FullCitation": "Ettl J, et al. Ann. Oncol. (2018) pmid: 30124753", "Include": "true"}, {"number": "287", "ReferenceId": "28242752", "FullCitation": "de Bono J, et al. Cancer Discov (2017) pmid: 28242752", "Include": "true"}, {"number": "288", "ReferenceId": "30099369", "FullCitation": "Lu E, et al. J Natl Compr Canc Netw (2018) pmid: 30099369", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_12_09 18:52:30", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "845x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PANCREAS", "disease_ontology": "Pancreas ductal adenocarcinoma", "flowcell_analysis": "2000025529", "gender": "male", "pathology_diagnosis": "Pancreatic Cancer; C25.9, C25", "percent_tumor_nuclei": "30", "pipeline_version": "v3.16.0", "purity_assessment": "35.8", "specimen": "ORD_1514793_01*US1450102.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1514793_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Pancreas", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "832.53", "name": "SQ_US1450102.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.1746", "cds_effect": "574C>T", "depth": "716", "equivocal": "false", "functional_effect": "nonsense", "gene": "TP53", "percent_reads": "17.46", "position": "chr17:7578275", "protein_effect": "Q192*", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.6021", "cds_effect": "225C>G", "depth": "475", "equivocal": "false", "functional_effect": "missense", "gene": "AKT1", "percent_reads": "60.21", "position": "chr14:105243058", "protein_effect": "I75M", "status": "unknown", "strand": "_", "transcript": "NM_001014431", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.4832", "cds_effect": "6667A>G", "depth": "716", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "48.32", "position": "chr11:108196131", "protein_effect": "I2223V", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.1557", "cds_effect": "35G>A", "depth": "655", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "15.57", "position": "chr12:25398284", "protein_effect": "G12D", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.5814", "cds_effect": "3664G>A", "depth": "657", "equivocal": "false", "functional_effect": "missense", "gene": "PTCH1", "percent_reads": "58.14", "position": "chr9:98211491", "protein_effect": "D1222N", "status": "unknown", "strand": "_", "transcript": "NM_000264", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.4936", "cds_effect": "2900G>A", "depth": "859", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB3", "percent_reads": "49.36", "position": "chr12:56493492", "protein_effect": "R967K", "status": "unknown", "strand": "+", "transcript": "NM_001982", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.4793", "cds_effect": "4071_4072insGATT", "depth": "482", "equivocal": "false", "functional_effect": "frameshift", "gene": "MSH6", "percent_reads": "47.93", "position": "chr2:48033987", "protein_effect": "K1358fs*2", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.1762", "cds_effect": "6373_6374insA", "depth": "715", "equivocal": "false", "functional_effect": "frameshift", "gene": "BRCA2", "percent_reads": "17.62", "position": "chr13:32914865", "protein_effect": "T2125fs*4", "status": "likely", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.483", "cds_effect": "1967C>T", "depth": "648", "equivocal": "false", "functional_effect": "missense", "gene": "DIS3", "percent_reads": "48.3", "position": "chr13:73337659", "protein_effect": "A656V", "status": "unknown", "strand": "_", "transcript": "NM_001128226", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.5974", "cds_effect": "812G>A", "depth": "765", "equivocal": "false", "functional_effect": "missense", "gene": "SMAD4", "percent_reads": "59.74", "position": "chr18:48584734", "protein_effect": "S271N", "status": "unknown", "strand": "+", "transcript": "NM_005359", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.4903", "cds_effect": "1189A>G", "depth": "822", "equivocal": "false", "functional_effect": "missense", "gene": "IDH2", "percent_reads": "49.03", "position": "chr15:90628130", "protein_effect": "M397V", "status": "unknown", "strand": "_", "transcript": "NM_002168", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.1682", "cds_effect": "247C>T", "depth": "535", "equivocal": "false", "functional_effect": "missense", "gene": "CDKN2A", "percent_reads": "16.82", "position": "chr9:21971111", "protein_effect": "H83Y", "status": "known", "strand": "_", "transcript": "NM_000077", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}, {"allele_fraction": "0.4748", "cds_effect": "1685C>T", "depth": "596", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "47.48", "position": "chr12:115112055", "protein_effect": "A562V", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1450102.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}